Urovant Sciences, Inc
United States
119 articles about Urovant Sciences, Inc
-
Her career as a physician and scientist is guided by a combination of logic and creativity.
-
Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients
11/8/2021
Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients
-
Urovant Sciences Announces Leadership Appointments to Drive Future Growth and Geographic Expansion
10/18/2021
Laura Genatossio Appointed Senior Vice President and General Manager, Europe Alana Darden Powell Promoted to Vice President, Corporate Communications Mark Niemaszek Named Senior Vice President, Corporate Planning Ted Chan Promoted to Senior Vice President, Associate General Counsel and Head of Intellectual Property
-
Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (vibegron) 75 mg in Overactive Bladder Was Not Associated with Statistically Significant or Clinically Meaningful Effects on Blood Pressure or Heart Rate
9/13/2021
Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA ® (vibegron) 75 mg in Overactive Bladder Was Not Associated with Statistically Significant or Clinically Meaningful Effects on Blood Pressure or Heart Rate
-
Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for Overactive Bladder at the Virtual 2021 Annual Meeting of the American Urological Association
9/3/2021
Urovant Sciences, Inc., a wholly-owned subsidiary of Sumitovant Biopharma Ltd., updates its news release originally issued August 18, 2021, to highlight the company’s participation at the 2021 annual meeting of the American Urological Association.
-
Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for Overactive Bladder at the 2021 Annual Meeting of the American Urological Association
8/18/2021
Urovant Sciences, Inc., a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced key data for GEMTESA® (vibegron) 75 mg to be presented at the 2021 Annual Meeting of the American Urological Association (AUA2021).
-
Urovant Sciences Appoints Betzy Estrada as Executive Vice President and Chief Human Resources Officer
8/12/2021
Urovant Sciences, Inc. today announced the appointment of Betzy Estrada as executive vice president and chief human resources officer.
-
Urovant Sciences Named One of the 2021 Best Places to Work in Orange County
7/6/2021
Urovant Sciences, a wholly owned subsidiary of Sumitovant, has been named as one of the 2021 Best Places to Work in Orange County.
-
Urovant Sciences and Sunovion Pharmaceuticals Launch Primary Care Co-Promotion of GEMTESA® (vibegron) for Patients with Overactive Bladder
6/29/2021
Urovant Sciences, Inc. and Sunovion Pharmaceuticals Inc. today announced the launch of co-promotion activities for GEMTESA® (vibegron) 75 mg tablets to extend promotion to primary care physicians through the deployment of Sunovion’s multi-specialty sales.
-
Urovant Sciences Announces Publication of Positive Long-Term Clinical Safety and Efficacy Data on the FDA-Approved Overactive Bladder Therapy, GEMTESA® (vibegron), in the Journal of Urology
4/15/2021
Urovant Sciences Announces Publication of Positive Long-Term Clinical Safety and Efficacy Data on the FDA-Approved Overactive Bladder Therapy, GEMTESA® (vibegron), in the Journal of Urology
-
Urovant Sciences Announces U.S. Commercial Launch of GEMTESA® (vibegron) 75 mg Tablets for Patients with Overactive Bladder
4/12/2021
Urovant Sciences Announces U.S. Commercial Launch of GEMTESA ® (vibegron) 75 mg Tablets for Patients with Overactive Bladder Nationwide availability gives healthcare providers and patients a new treatment option
-
The American Urological Association and Urology Care Foundation Unveil New Urology Research Program Supported by $2 Million Donation from Urovant Sciences
4/1/2021
The American Urological Association and Urology Care Foundation announced the launch of a program aimed at fostering diversity and inclusion in urology research, supported by a generous $2 million donation from Urovant Sciences.
-
Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and Safety Monitoring Board
2/11/2021
Urovant Sciences (Nasdaq: UROV) announced today that the independent Data and Safety Monitoring Board (DSMB) has recommended the continuation of the phase 2a study of URO-902, a novel gene therapy product, in patients with overactive bladder (OAB) and urge urinary incontinence (UUI).
-
Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
12/23/2020
Urovant Sciences Announces U.S. FDA Approval of GEMTESA ® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB) GEMTESA is the first new oral branded OAB medication approved by the U.S. FDA since 2012 and the first product approval for Urovant Sciences U.S. commercial launch planned in late-Q1 2021 IRVINE, Calif. & BASEL, Switzerland--( BUSINESS WIRE )-- Urovant Sciences (Nasdaq: UROV) announced today that th
-
The U.S. FDA is plenty busy with COVID-19 vaccine Emergency Use Authorizations this month, but they’re also wrapping up the year with a few PDUFA dates for other therapies. Here’s a look.
-
Clinical Catch-Up: November 23-27
11/30/2020
As the U.S. went into its Thanksgiving holiday week, clinical trial news was quieter than usual, although there was a lot of important news on the COVID-19 vaccine front. Here’s a look. -
Even companies with otherwise promising pipelines or successful products on the market sometimes face clinical trial failures. Two such companies had disappointing clinical trial announcements today.
-
Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint
11/24/2020
Urovant Sciences (Nasdaq: UROV) today reported topline data from the Phase 2a randomized, double blind, placebo-controlled clinical trial evaluating once-daily vibegron 75 mg in women with abdominal pain due to irritable bowel syndrome (IBS) with IBS-D (diarrhea) and IBS-M (mixed IBS).
-
Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension Study
11/19/2020
Urovant Sciences (Nasdaq: UROV) today announced positive efficacy and safety data from the vibegron EMPOWUR long term extension study with patient data over a total exposure of 52 weeks.
-
In a deal set to be finalized early in 2021, Urovant Sciences has agreed to be fully acquired by largest investor and close partner, Sumitovant Biopharma.